Abstracts tagged "Lupus"

Abstract Number: 1764 • 2015 ACR/ARHP Annual Meeting
Type 1 Interferon in the Skin Stimulated By Ultraviolet B Light Generates Immune Suppression Mediated By Idoleamine 2,3-Dioxygenase 1
Clayton Sontheimer¹ and Keith B. Elkon², ¹Pediatric Rheumatology, University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Photosensitivity is a common symptom in patients with systemic lupus erythematosus (SLE) and lupus skin lesions show local Type 1 Interferon (IFN-I) profiles similar…
Abstract Number: 2083 • 2015 ACR/ARHP Annual Meeting
Predictors of Health Perceptions Among Women with Lupus
Patricia P. Katz¹, Eliza Chakravarty², Robert S. Katz³ and Kaleb Michaud⁴, ¹Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Rush University Medical Center, Chicago, IL, ⁴Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Health perceptions, such as self-rated health, have been shown to predict multiple adverse health outcomes and to have a strong socioeconomic status (SES) gradient. …
Abstract Number: 402 • 2015 ACR/ARHP Annual Meeting
Predicting Area Under the Curve of Mycophenolate Mofetil in Childhood-Onset Systemic Lupus Erythematosus
Roberto Ezequiel Borgia¹, Masanobu Takeuchi², Deborah M. Levy³, Shinya Ito‎⁴ and Earl Silverman⁵, ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Program of Physiology & Experimental Medicine, Peter Gilgan Centre For Research and Learning (PGCRL), The Hospital for Sick Children, Toronto ON, Toronto, ON, Canada, ³Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴3Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children Toronto ON, Toronto, ON, Canada, ⁵Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Mycophenolate mofetil (MMF) is an immunosuppressive drug used off-label for the treatment of childhood-onset systemic lupus erythematosus (cSLE). Therapeutic drug monitoring (TDM) of MMF’s…
Abstract Number: 814 • 2015 ACR/ARHP Annual Meeting
Lupus Drives Atherosclerosis through CD4+CXCR3+ T Cells and Plasmacytoid Dendritic Cells
Tiphaine Goulenok¹, Marc Clement², Nicolas Charles³, Brigitte Escoubet⁴, Marie-Paule Chauveheid⁵, Thomas Papo⁶ and Karim Sacre⁷, ¹University Paris Diderot - APHP - Bichat Hospital, aris, France, ²University Paris Diderot - INSERM U1148, Paris, France, ³INSERM U699, Paris, France, ⁴University Paris- Diderot - APHP - Hôpital Bichat, Paris, France, ⁵Internal Medicine, Bichat-Claude Bernard Hospital, University Paris-7, Paris, France, ⁶CHU Bichat, Paris, France, ⁷Internal Medicine, University Paris-7, INSERM U1149, APHP, Bichat Hospital, Paris, France
Background/Purpose: Accelerated atherosclerosis is the leading cause of death in systemic lupus erythematosus (SLE). How SLE promotes accelerated atherosclerosis remains elusive. The purpose of this…
Abstract Number: 1777 • 2015 ACR/ARHP Annual Meeting
Lymphocyte Depletion, Recovery and Efficacy in NZBWF1 Lupus Mice Following Continuous or Intermittent Dosing Regimen of Venetoclax (ABT-199), a Potent and Selective BCL-2 Inhibitor
Li Chun Wang¹, Stuart Perper¹, Kimberly Black¹, Regina Mario¹, Candace Graff^2,3, Dawna Hartman³, Andrew Souers⁴, Steven Elmore⁴ and Lisa Olson^1,3, ¹Immunology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²DMPK, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ³AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Proteins in the BCL-2 family are key regulators of apoptosis, or programmed cell death. We report here that continuous daily treatment with 30mpk venetoclax…
Abstract Number: 2221 • 2015 ACR/ARHP Annual Meeting
Engaging Learners in Lupus Education with Pivot (Practice Improvement using Virtual Online Training), a Novel, Digital Case-Based Curriculum
Karen Law¹, Michelle Lin², Sheryl McCalla³ and Maria Dall'Era⁴, ¹Emory University School of Medicine, Atlanta, GA, ²Emergency Medicine, UCSF, San Francisco, CA, ³American College of Rheumatology, Atlanta, GA, ⁴University of California San Francisco School of Medicine, San Francisco, CA
Background/Purpose: Lupus is one of the prototypic rheumatic diseases, yet only a small amount of time in medical school curricula is devoted to lupus-specific education.…
Abstract Number: 422 • 2015 ACR/ARHP Annual Meeting
Mood Disorder Is Highly Prevalent in a Multi-Ethnic Urban Pediatric Lupus Cohort
Tamar Rubinstein^1,2, Dawn Wahezi^1,2, Jay Mehta^3,4, Norman Ilowite^3,5, Debbie Rybak⁶, Jordan Brodsky⁶, Nicole Jordan⁶, Ruth Stein^5,7 and Chaim Putterman⁶, ¹Pediatric Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ³Division of Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ⁴Division of Pediatric Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁵Pediatrics, Albert Einstein College of Medicine, Bronx, NY, ⁶Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁷Pediatrics, Children's Hospital at Montefiore, Bronx, NY
Background/Purpose: While mood disorder, most commonly manifesting as depression and anxiety symptoms, is often reported in pediatric lupus patients, prevalence rates vary widely. Many published…
Abstract Number: 815 • 2015 ACR/ARHP Annual Meeting
Lys63-Polyubiquitination By the E3 Ligase Casitas B-Lineage Lymphoma-b Modulates Peripheral Regulatory T Cell Tolerance in Patients with Systemic Lupus Erythematosus
Diana Gómez-Martín¹, Jorge Alcocer-Varela¹, Jorge Romo-Tena¹, Ana Barrera-Vargas¹ and Javier Merayo-Chalico², ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: The interplay between effector and regulatory T cells (Tregs) is a key element among peripheral tolerance mechanisms in Systemic Lupus Erythematosus (SLE). Resistance to…
Abstract Number: 1779 • 2015 ACR/ARHP Annual Meeting
Characterization of Anti-Nuclear Antibody (ANA) Signatures in Murine Models of Lupus Using Genalyte Maverick Technology
Jacqueline Loud¹, Stuart Perper², Rachel Twomey² and Stephen Clarke², ¹Immunology Pharmacology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²Immunology Pharmacology, Abbvie Bioresearch Center Inc., Worcester, MA
Background/Purpose: Systemic lupus erythematosus (SLE) and lupus nephritis (LN) are autoimmune diseases characterized by circulating antibodies to nuclear self-antigens, including reactivities to double-stranded DNA, RNP…
Abstract Number: 2512 • 2015 ACR/ARHP Annual Meeting
Depot Medroxyprogesterone Acetate Birth Control May Suppress Toll-like Receptor 7-Induced Interferon-Alpha Production By Plasmacytoid Dendritic Cells in Women
Yuli McCann¹, Meredith Barnes¹ and Grant Hughes², ¹Medicine, University of Washington, Seattle, WA, ²Medicine/Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Female sex steroids are important modulators of autoimmunity. Estrogen appears to favor the development of lupus autoimmunity via activation of adaptive and innate immune…
Abstract Number: 423 • 2015 ACR/ARHP Annual Meeting
Institutional and Regional Variation in Childhood SLE 30-Day Hospital Readmission Rates: A Comparative Effectiveness Research Using the Pediatric Health Information System Database
Breanna Beltz¹, Mohammad Shah², Mary Toth³ and Moussa El-Hallak⁴, ¹Hiram College, Akron, OH, ²Patient Safety and Quality Services, Akron Children's Hospital, Akron, OH, ³Rheumatology, Akron Children's Hospital, Akron, OH, ⁴Dept of Pediatric Rheumatology, Akron Children's Hospital, Akron, OH
Background/Purpose: Early hospital readmission is emerging as an indicator of care quality. The reported 30-day hospital readmission (30-DHR) rate for pediatric patients is 6.5%. However,…
Abstract Number: 932 • 2015 ACR/ARHP Annual Meeting
IRF4-Dependent and IRF4-Independent Pathways Contribute to DC Dysfunction in Lupus
Michela Manni¹, Sanjay Gupta², Briana G. Nixon³ and Alessandra B. Pernis⁴, ¹Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, ²Autoimmunity & Inflammation Research Program, Hospital for Special Surgery, New York, NY, ³Graduate Program in Immunology and Microbial Pathogenesis, Weill Cornell Graduate School of Medical Sciences, New York, NY, ⁴Autoimmunity & Inflammation, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Interferon Regulatory Factors (IRFs) play fundamental roles in dendritic cell (DC) differentiation and function. In particular IRFs are critical transducers of Toll-like Receptors (TLR)…
Abstract Number: 1786 • 2015 ACR/ARHP Annual Meeting
Improvements in Health-Related Quality of Life and Fatigue Following Administration of an IL-6 Monoclonal Antibody (PF-04236921) in an Enriched Population of Subjects with Active SLE
Vibeke Strand¹, Annette Diehl², Jared Christensen², Joseph Wajdula², Sudhakar Sridharan³ and Paul J Healey², ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Pfizer Inc, New York City, NY, ³PPD Inc, Rockville, MA
Background/Purpose: The 10 mg dose of PF-04236921 showed evidence of efficacy in a phase 2 randomized controlled trial (RCT) in SLE.1,2 Here patient-reported outcomes (PROs)…
Abstract Number: 2529 • 2015 ACR/ARHP Annual Meeting
Decreased Programmed Death Ligand-1 (PD-L1) in Systemic Lupus Erythematosus (SLE) Placenta
Gail Deutsch^1,2, Megan Yuasa³ and Anne M. Stevens^4,5, ¹Pathology, Seattle Children's Hospital, Seattle, WA, ²School of Medicine, University of Washington, Seattle, WA, ³Seattle Children's Res Institute, Seattle Children's Research Institute, Seattle, WA, ⁴Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, ⁵Pediatrics, University of Washington, Seattle, WA
Background/Purpose: The increased rates of preeclampsia, preterm birth, and intrauterine growth restriction in SLE pregnancy are only partially explained by the vascular effects of anti-phospholipid…
Abstract Number: 741 • 2015 ACR/ARHP Annual Meeting
Satisfaction and Impact Associated with the Addition of Belimumab to Systemic Lupus Erythematosus (SLE) Treatment: A Cross-Sectional Survey of US Rheumatologists and Their Patients
Katie Pascoe¹, Steve Lobosco², David Bell³, Ben Hoskin³, Sulabha Ramachandran⁴, Bonnie Pobiner⁵ and David Chang⁶, ¹Value Evidence and Outcomes, GlaxoSmithKline, Uxbridge, United Kingdom, ²Adelphi Real World Ltd., Macclesfield, United Kingdom, ³Autoimmune, Adelphi Real World Ltd., Manchester, United Kingdom, ⁴Value Evidence and Outcomes, GlaxoSmithKline, Renaissance Centre, PA, ⁵Immuno-Inflammation Therapy Area, GlaxoSmithKline, Triangle Park, NC, ⁶US Medical Affairs, GlaxoSmithKline, Philadelphia, PA
Background/Purpose: Patient and physician treatment satisfaction influences long-term adherence with a treatment regimen. The primary objective was to identify factors linked to satisfaction with the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].